Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: Systematic review and meta-analysis

Eye (Basingstoke)

Volumn 28, Issue 7, 2014, Pages 788-796

  Faes, L ^a   Bodmer, N S ^a   Bachmann, L M ^a   Thiel, M A ^b   Schmid, M K ^b  

^a MEDIGNITION INC   (Switzerland)

^b LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMSLER CHART; CASE CONTROL STUDY; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MEDLINE; META ANALYSIS; PATIENT CARE; PERIMETRY; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SCREENING; SYSTEMATIC REVIEW; TASK PERFORMANCE;

EID: 84922008821     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.104     Document Type: Review

References (32)

1. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124(11): 1532-1542. (Pubitemid 44748725)
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431. (Pubitemid 44511557)
3. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-1908.
4. Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120(1): 122-129.
5. Amsler M. L'Examen qualitatif de la fonction maculaire. Ophthalmologica 1947; 114: 248-261.
6. Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H et al. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005; 25(3): 296-303. (Pubitemid 40517358)
7. Kaiser PK, Wang YZ, He YG, Weisberger A, Wolf S, Smith CH. Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: Results of a pilot study. Retina 2013; 33(9): 1863-1870.
8. Wang YZ, Wilson E, Locke KG, Edwards AO. Shape discrimination in age-related macular degeneration. Invest Ophthalmol Vis Sci 2002; 43(6): 2055-2062. (Pubitemid 34587060)
9. Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012; 153(4): 678-686; 686 e671-672.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-Analyses: The PRISMA statement. BMJ 2009; 339: B2535.
11. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH et al. Empirical evidence of designrelated bias in studies of diagnostic tests. JAMA 1999; 282(11): 1061-1066. (Pubitemid 29436454)
12. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155(8): 529-536.
13. Harbord RM, Whiting P, Sterne JA, Egger M, Deeks JJ, Shang A et al. An empirical comparison of methods for meta-Analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008; 61(11): 1095-1103.
14. Zwinderman AH, Bossuyt PM. We should not pool diagnostic likelihood ratios in systematic reviews. Stat Med 2008; 27(5): 687-697. (Pubitemid 351278813)
15. Chou R, Dana T, Bougatsos C. Screening older adults for impaired visual acuity: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 1511: 44-58; W11-20.
16. Crossland M, Rubin G. The Amsler chart: Absence of evidence is not evidence of absence. Br J Ophthalmol 2007; 91(3): 391-393. (Pubitemid 46586541)
17. Bachmann LM, Juni P, Reichenbach S, Ziswiler HR, Kessels AG, Vogelin E. Consequences of different diagnostic "gold standards" in test accuracy research: Carpal Tunnel Syndrome as an example. Int J Epidemiol 2005; 34(4): 953-955. (Pubitemid 41418849)
18. Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the eye (HOME) study. Ophthalmology 2014; 121(2): 535-544.
19. Chhetri AP, Wen F, Wang Y, Zhang K. Shape discrimination test on handheld devices for patient self-Test. Proceedings of the 1st ACM International Health Informatics Symposium 2010, ACM New York, NY, USA 2010: 502-506.
20. Wang YZ, He YG, Mitzel G, Zhang S, Bartlett M. Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci 2013; 54(8): 5497-5505.
21. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986; 104(4): 513-514. (Pubitemid 16086332)
22. Nowomiejska K, Oleszczuk A, Brzozowska A, Grzybowski A, Ksiazek K, Maciejewski R et al. M-charts as a tool for quantifying metamorphopsia in age-related macular degeneration treated with the bevacizumab injections. BMC Ophthalmol 2013; 13: 13.
23. Alster Y, Bressler NM, Bressler SB, Brimacombe JA, Crompton RM, Duh YJ et al. Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology 2005; 112(10): 1758-1765. (Pubitemid 41400012)
24. Isaac DL, Avila MP, Cialdini AP. Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration. Arq Bras Oftalmol 2007; 70(5): 771-776.
25. Lai Y, Grattan J, Shi Y, Young G,Muldrew A, Chakravarthy U. Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter. Retina 2011; 31(8): 1620-1626.
26. Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E et al. Replacing the Amsler grid: A new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003; 110(5): 966-970. (Pubitemid 36560498)
27. Loewenstein A, Ferencz JR, Lang Y, Yeshurun I, Pollack A, Siegal R et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: Multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina 2010; 30(7): 1058-1064.
28. Mathew R, Sivaprasad S. Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration. Eye 2012; 26(3): 389-393.
29. Robison CD, Jivrajka RV, Bababeygy SR, Fink W, Sadun AA, Sebag J. Distinguishing wet from dry age-related macular degeneration using three-dimensional computer-Automated threshold Amsler grid testing. Br J Ophthalmol 2011; 95(10): 1419-1423.
30. Arimura E, Matsumoto C, Nomoto H, Hashimoto S, Takada S, Okuyama S et al. Correlations between M-CHARTS and PHP findings and subjective perception of metamorphopsia in patients with macular diseases. Invest Ophthalmol Vis Sci 2011; 52(1): 128-135.
31. Klatt C, Sendtner P, Ponomareva L, Hillenkamp J, Bunse A, Gabel VP et al. Diagnostics of metamorphopsia in retinal diseases of different origins. Ophthalmologe 2006; 103(11): 945-952. (Pubitemid 44769919)
32. Kampmeier J, Zorn MM, Lang GK, Botros YT, Lang GE. [Comparison of Preferential Hyperacuity Perimeter (PHP) test and Amsler grid test in the diagnosis of different stages of age-related macular degeneration]. Klin Monbl Augenheilkd 2006; 223(9): 752-756. (Pubitemid 44681429)